Ask AI
ProCE Banner Activity

Are We Treating HBV Early Enough?

Video

Join expert faculty as they answer important questions about how to expand HBV treatment candidacy for early treatment engagement, including adverse event considerations, cost-effectiveness, and clinical outcomes such as the potential impact on liver disease progression and HCC rates.

Released: March 07, 2024

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD: consultant/advisor/speaker: GlaxoSmithKline.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Eiger, Gilead, GlaxoSmithKline; researcher: Gilead.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor/speaker: Aligos, Drug Farm, Eiger, Gilead, Inventiva; researcher: Altimmune, Bristol Myers Squibb, Eiger, Gilead, Janssen, Madrigal, Novo Nordisk, Salix, Ultragenyx.

Mark Sulkowski, MD, FAASLD

Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark Sulkowski, MD, FAASLD: consultant/advisor/speaker: AbbVie, Aligos, GSK, Precision Biosciences, Vir, Virion; data and safety monitoring board: Gilead; researcher: Aligos, GSK, Vir.